Debt-to-equity in % of Lineage Cell Therapeutics, Inc. from Q1 2017 to Q3 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Lineage Cell Therapeutics, Inc. quarterly Debt-to-equity history and change rate from Q1 2017 to Q3 2025.
  • Lineage Cell Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 80.3 %, a 50.4% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Lineage Cell Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 80.3 +26.9 +50.4% 30 Sep 2025
Q2 2025 53.6 -2.2 -3.94% 30 Jun 2025
Q1 2025 47.3 -9.26 -16.4% 31 Mar 2025
Q4 2024 49.6 -9.81 -16.5% 31 Dec 2024
Q3 2024 53.4 -8.44 -13.7% 30 Sep 2024
Q2 2024 55.8 -8.5 -13.2% 30 Jun 2024
Q1 2024 56.6 -10.2 -15.3% 31 Mar 2024
Q4 2023 59.4 -8.71 -12.8% 31 Dec 2023
Q3 2023 61.8 -11.9 -16.1% 30 Sep 2023
Q2 2023 64.3 +9.64 +17.6% 30 Jun 2023
Q1 2023 66.7 +27.7 +70.8% 31 Mar 2023
Q4 2022 68.1 +42.2 +163% 31 Dec 2022
Q3 2022 73.7 +63.5 +621% 30 Sep 2022
Q2 2022 54.7 +43.4 +387% 30 Jun 2022
Q1 2022 39.1 +26.4 +207% 31 Mar 2022
Q4 2021 25.9 +12.1 +87.6% 31 Dec 2021
Q3 2021 10.2 -3.34 -24.6% 30 Sep 2021
Q2 2021 11.2 -2.58 -18.7% 30 Jun 2021
Q1 2021 12.7 -1.27 -9.08% 31 Mar 2021
Q4 2020 13.8 -0.33 -2.34% 31 Dec 2020
Q3 2020 13.6 -0.18 -1.31% 30 Sep 2020
Q2 2020 13.8 +3.35 +32% 30 Jun 2020
Q1 2020 14 +5.25 +60.1% 31 Mar 2020
Q4 2019 14.1 +7.36 +109% 31 Dec 2019
Q3 2019 13.8 +7.96 +138% 30 Sep 2019
Q2 2019 10.5 +3.82 +57.5% 30 Jun 2019
Q1 2019 8.74 +1.68 +23.8% 31 Mar 2019
Q4 2018 6.76 -0.5 -6.89% 31 Dec 2018
Q3 2018 5.79 -2.4 -29.3% 30 Sep 2018
Q2 2018 6.64 -2.36 -26.2% 30 Jun 2018
Q1 2018 7.06 -2.58 -26.8% 31 Mar 2018
Q4 2017 7.25 31 Dec 2017
Q3 2017 8.18 30 Sep 2017
Q2 2017 9 30 Jun 2017
Q1 2017 9.64 31 Mar 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.